| THE UNIVERSITY OF EDINBURGH Patent applications |
| Patent application number | Title | Published |
|---|
| 20120095046 | Amido-Isothiazole Compounds and Their Use as Inhibitors of 11Beta-HSD1 for the Treatment of Metabolic Syndrome and Related Disorders - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-isothiazole compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 04-19-2012 |
| 20120057540 | OUT-OF-GROUP INTERFERENCE REDUCTION IN WIRELESS COMMUNICATION SYSTEMS - In a MIMO wireless communication system, a plurality of base stations (BSs) are provided each of which can transmit signals to, and receive signals transmitted from, one or more user equipments (UEs). The BSs are also organised into a plurality of groups. In a given group of BSs serving one or more UEs, those serving BSs coordinate with each other to simultaneously transmit signals to the one or more served UEs, and one or more of the served UEs feed back information to one or more of those serving BSs. The fed back information incorporates inter-group noise information related to interference between different BS groups. The method involves processing signals for simultaneous transmission by BSs of a group to one or more UEs served by that group and using the information fed back to the BSs of that group to improve system performance. | 03-08-2012 |
| 20110015178 | Amido-Thiophene Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 01-20-2011 |
| 20100267696 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc. | 10-21-2010 |
| 20100144039 | Pluripotency determining factors and uses thereof - Pluripotency determining factors are described which act intracellularly and maintain a pluripotent cell in a pluripotent state in the absence of gp130 activation, which maintain or confer pluripotency of a human stem cell, which maintain or confer pluripotency of a mouse ES cell, and which maintain or confer pluripotency of a stem cell from a non-permissive strain of mice. The factors and vectors encoding or activating the factors are used to maintain and derive pluripotent cells, especially of higher mammals, including humans. | 06-10-2010 |
